Evaluation of Posaconazole Serum Concentrations Achieved With Delayed-release Tablets and Oral Suspension in Patients Undergoing Intensive Chemotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome

被引：0
|
作者：
Muehlberg, Leonora [1 ]
Pabst, Thomas [2 ]
Largiader, Carlo [3 ,4 ]
Aebi, Yolanda [3 ,4 ]
Hayoz, Michael [3 ,4 ]
Muehlethaler, Konrad [5 ]
Zimmerli, Stefan [1 ]
Hirzel, Cedric [1 ]
机构：
[1] Univ Bern, Bern Univ Hosp, Dept Infect Dis, Inselspital, Bern, Switzerland
[2] Bern Univ Hosp, Dept Med Oncol, Inselspital, Bern, Switzerland
[3] Bern Univ Hosp, Dept Clin Chem, Inselspital, Bern, Switzerland
[4] Univ Bern, Bern, Switzerland
[5] Univ Bern, Inst Infect Dis, Dept Clin Microbiol, Bern, Switzerland
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 05期
关键词：
acute myeloid leukemia; intensive chemotherapy; myelodysplastic syndrome; posaconazole prophylaxis; PRIMARY ANTIFUNGAL PROPHYLAXIS; CLINICAL-EFFICACY; ALLOGENEIC BLOOD; FLUCONAZOLE; SAFETY; ITRACONAZOLE;
D O I：
10.1093/ofid/ofae263
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Data on posaconazole serum levels of patients on prophylaxis with delayed-release tablets or oral suspension during intensive chemotherapy for acute myeloid leukemia and myelodysplastic syndrome are scarce. In this analysis, the proportion of patients with acute myeloid leukemia/myelodysplastic syndrome achieving posaconazole target concentrations with delayed-release tablets was higher than with oral suspension.
引用
下载
收藏
页数：4
相关论文
共 25 条
  • [1] Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies
    Cumpston, Aaron
    Caddell, Ryan
    Shillingburg, Alexandra
    Lu, Xiaoxiao
    Wen, Sijin
    Hamadani, Mehdi
    Craig, Michael
    Kanate, Abraham S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4424 - 4428
  • [2] Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections
    Chin, Alan
    Pergam, Steven A.
    Fredricks, David N.
    Hoofnagle, Andrew N.
    Baker, Kelsey K.
    Jain, Rupali
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (10)
  • [3] Evaluation of posaconazole plasma concentrations achieved with the delayed-release tablets in Korean high-risk patients with haematologic malignancy
    Chae, Hyojin
    Cho, Sung-Yeon
    Yi, Yunmi
    Lee, Jeong Joong
    Cha, Kyoungho
    Kim, Myungshin
    Kim, Yonggoo
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Dong-Gun
    MYCOSES, 2020, 63 (02) : 131 - 138
  • [4] Factors Influencing Serum Posaconazole Concentrations in Patients With Hematologic Malignancies Receiving Delayed-Release Tablets
    Yamada, Takaaki
    Belabbas, Tassadit
    Suetsugu, Kimitaka
    Hirota, Takeshi
    Mori, Yasuo
    Kato, Koji
    Akashi, Koichi
    Egashira, Nobuaki
    Ieiri, Ichiro
    THERAPEUTIC DRUG MONITORING, 2024, 46 (05) : 603 - 610
  • [5] Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
    J. J. Vehreschild
    C. Müller
    F. Farowski
    M. J. G. T. Vehreschild
    O. A. Cornely
    U. Fuhr
    K.-A. Kreuzer
    M. Hallek
    V. Kohl
    European Journal of Clinical Pharmacology, 2012, 68 : 987 - 995
  • [6] Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome
    Vehreschild, J. J.
    Mueller, C.
    Farowski, F.
    Vehreschild, M. J. G. T.
    Cornely, O. A.
    Fuhr, U.
    Kreuzer, K. -A.
    Hallek, M.
    Kohl, V.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (06) : 987 - 995
  • [7] Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy
    Delavigne, Karen
    Berard, Emilie
    Bertoli, Sarah
    Corre, Jill
    Duchayne, Eliane
    Demur, Cecile
    Mansat-De Mas, Veronique
    Borel, Cecile
    Picard, Muriel
    Alvarez, Muriel
    Sarry, Audrey
    Huguet, Francoise
    Recher, Christian
    HAEMATOLOGICA, 2014, 99 (03) : 474 - 480
  • [8] Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
    Krishna, Gopal
    AbuTarif, Malaz
    Xuan, Fengjuan
    Martinho, Monika
    Angulo, David
    Cornely, Oliver A.
    PHARMACOTHERAPY, 2008, 28 (10): : 1223 - 1232
  • [9] Factors influencing pharmacokinetics of prophylactic posaconazole oral solution in patients with acute myeloid leukemia or myelodysplastic syndrome
    Vehreschild, J. -J
    Mueller, C.
    Farowski, F.
    Vehreschild, M. J. G. T.
    Cornely, O. A.
    Fuhr, U.
    Kreuzer, K. -A
    Hallek, M.
    Kohl, V
    ONKOLOGIE, 2011, 34 : 77 - 77
  • [10] Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study
    Copley, Melissa S.
    Waldron, Madeline
    Athans, Vasilios
    Welch, Sarah C.
    Brizendine, Kyle D.
    Cober, Eric
    Siebenaller, Caitlin
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (03)
123